The beneficial effect of corticosteroids in asthma is undoubted. In patients with chronic bronchitis, emphysema, or both, who have chronic airways obstruction with little or no response to inhaled bronchodilator drugs, the effect of corticosteroids is debatable.
Previous studies of this problem have come to widely differing conclusions (see Discussion). The most carefully conducted and controlled studies suggest that prednisone is not helpful.
Despite this evidence, it is common practice to give a trial of steroids to patients with severe dyspnoea not helped by bronchodilators. In the individual case it may be difficult to distinguish a moderate response to prednisone from spontaneous slow fluctuations in the disease. Nevertheless it was our impression that some patients do respond to steroids and also that they may respond to a small dose. We therefore designed a controlled double-blind cross-over trial of prednisone, 5 mg per day by mouth, in patients with chronic airways obstruction and used measurements of forced Present address:
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The patients were asked if they would take part in a trial of a drug which might be beneficial to them, and willingly agreed to participate. The study was approved by the hospital committee on ethical procedures. A short account of this work has been given previously (Evans, Morrison, and Saunders, 1973) .
SUBJECTS
We studied 10 men with chronic diffuse airways obstruction and little or no response to bronchodilator therapy (Table I) . Their ages ranged from 50 to 72 (mean 62). All were smokers or ex-smokers. All had chronic cough with sputum (on most days for at least three months of the year, for at least two years) and in all the main complaint was of breathlessness. None had a family or personal history suggestive of atopy. The lung function studies were carried out on three occasions, first immediately before starting the trial ('pre-trial') and again after the first and second weeks of treatment ('placebo' or 'prednisone').
The following measurements were made, in the same order, at each attendance, between 14.00 and 16.00 hours.
1. FORCED EXPIRATORY VOLUMES We measured forced expiratory volumes in 1 second (FEVy), forced vital capacity (FVC), and the FEV,/FVC ratio with a dry spirometer (Collins, McDermott, and McDermott, 1964) , obtained three technically satisfactory blows at approximately one minute intervals, and took the mean of the highest two values for each variable.
INSPIRATORY AIRWAYS RESISTANCE (Raw) AND SPE-
CIFIC CONDUCTANCE (SGaw) We used a constant volume whole body plethysmograph (Dubois et al., 1956a; Dubois, Botelho and Comroe, 1956b) with the patient in the semi-reclining position. Thoracic gas volume (TGV) was measured by the airway occlusion technique. The relation between alveolar pressure and flow was displayed on a storage oscilloscope (Tektronix 564B). Slope measurements for derivation of Raw were made on the inspiratory portion of the trace, the expiratory phase being widely looped in these patients. The means of three measurements of TGV and of Raw were taken, and SGaw was calculated as the conductance, or reciprocal of Raw, divided by TGV.
3. RESPONSE TO ISOPRENALINE When the above measurements were completed the patient received two inhalations of isoprenaline aerosol from a metereddose container (Medihaler Iso Forte) and the measurements of FEV1, FVC, and FEV,/FVC were repeated. Two patients (1 and 7) declined this part of the procedure because of previous side effects from similar therapy.
4. BLOOD GAS ANALYSIS Finally, a sample of blood was taken under local anaesthesia from the brachial artery and analysed for the partial pressure of oxygen (Pao2), carbon-dioxide (Paco2), and pH with Radiometer electrodes. Pao2 measurements were not obtained in patients 7 and 8.
RADIOLOGICAL ASSESSMENT The chest radiographs of all subjects were examined by an independent observer (Dr. J. W. Pierce) and assessed for the presence of emphysema with particular reference to the nature of peripheral vascular markings (Laws and Heard, 1962) . The films were divided into three groups: (1) no evidence of emphysema; (2) probable evidence of emphysema; and (3) definite emphysema. Each film was assessed on two separate occasions, the observer being unaware of the results of lung function tests and, during the second assessment, of his previous grading of the film. In fact the only two patients initially graded as 'probable' (5 and 9) were on the second occasion thought to show no evidence of emphysema and have been graded as such. The other eight films were given the same grading on both occasions. Since the subjects had fortuitously fallen into two equal groups with and without evidence of emphysema on the chest film, they were tested for differences between means for each group, for all variables described above, using an unpaired twotailed t test. No significant differences were found. followed changes in the other in individual patients, reflecting the fact that TGV was very similar on all three occasions when it was measured (with the one exception already mentioned). We include figures for SGaw to allow comparison with the results of others (Oppenheimer, Rigatto, and Fletcher, 1968) . Previous studies of the effect of prednisone in chronic airways obstruction have given variable, and generally discouraging, results. Earlier studies (Franklin, Michelson, Lowell, and Schiller, 1958; Corazza, Morrow, and Chesney, 1961; Clifton and Stuart-Harris, 1962; Freedman, 1963; Fuleihan, Feisal, and Malouf, 1967) were not controlled. Moyes and Kershaw (1957) concluded that there was no significant symptomatic benefit to chronic bronchitics given tetracycline plus prednisone, 15 mg/day, as opposed to tetracycline alone. Lung function studies were limited to vital capacity measurements. Oppenheimer et al. (1968) , in a controlled single-blind study using body plethysmography, found no significant benefit in patients given 20 mg prednisone for one week. Their patients had a mean FEV5 of 1P47 l., mean VC of 2-91 1., and mean SGaw of 0-103 cmH,O 1 sec't, suggesting that, as a group, they had less severe obstruction than ours (mean FEV, 111 1., FVC 2-28 1., SGaw 0-051 cmH2O-' sec-' in the pre-trial values). Indeed their mean value for SGaw of 0-103 falls not far below the lower limit of normal (0-13) obtained by Briscoe and Dubois (1958) , with which observations in our laboratory agree.
RESULTS
There appear to be only three double-blind trials other than our own. Beerel, Jick, and Tyler (1963) did not use body plethysmography and gave prednisone in high dosage (60 mg daily, decreasing to 20 mg on the third day, and continuing at that dose for two weeks in all). Marked improvement in FEVY was seen in two patients, but both had had episodes of wheezing since adolescence, which suggested an asthmatic basis for their symtoms. Beerel and Vance (1971) showed some improvement in arterial blood gases and pulmonary diffusing capacity in patients with emphysema given 60 mg prednisone daily initially, decreasing to a maintenance dose of 20 mg daily for eight weeks.
Seven of the 23 patients in this study had obvious side effects of steroids. Morgan and Rusche (1964) did use body plethysmography in five of seven subjects, and gave betamethasone, 3-6 mg daily for three days, and 1-8 mg daily thereafter, equivalent to 24 and 12 mg prednisone respectively. All five patients showed deterioration in measurements of airways resistance while on the active preparation, not only on body plethysmography but also in measurements derived from spirometry. We have now reached a similar conclusion giving only 5 mg prednisone daily.
We did not systematically investigate symptoms. All patients said they 'felt better' on the tablets but, more to the point, did not distinguish between placebo and active treatment.
It may have been assumed in the past that if steroids, in low dose, were given to patients with chronic airways obstruction, they would do no harm, even if they did no good. Our findings, in conjunction with those of Morgan and Rusche (1964) 
